Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 9/20 | 0.62 |
| ▸ | GABRA5 | P31644 | 9/20 | 0.62 |
| ▸ | GABRA3 | P34903 | 9/20 | 0.62 |
| ▸ | GABRA2 | P47869 | 8/20 | 0.62 |
| ▸ | GABRG2 | P18507 | 7/20 | 0.62 |
| ▸ | GABRB3 | P28472 | 7/20 | 0.62 |
| ▸ | GABRB2 | P47870 | 6/20 | 0.62 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | GABRP | O00591 | 3/20 | 0.50 |
| ▸ | GABRD | O14764 | 3/20 | 0.50 |
| ▸ | GABRB1 | P18505 | 3/20 | 0.50 |
| ▸ | GABRA4 | P48169 | 3/20 | 0.50 |
| ▸ | GABRE | P78334 | 3/20 | 0.50 |
| ▸ | GABRA6 | Q16445 | 3/20 | 0.50 |
| ▸ | GABRG1 | Q8N1C3 | 3/20 | 0.50 |
| ▸ | GABRG3 | Q99928 | 3/20 | 0.50 |
| ▸ | GABRQ | Q9UN88 | 3/20 | 0.50 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.45 |
| ▸ | CNR1 | P21554 | 1/20 | 0.45 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8547651 | 0.81 | GABRA1 (0.73) | GABRA1GABRA5GABRA3GABRA2GABRG2 | |
| SCHEMBL27587130 | 0.81 | GABRA1 (0.72) | GABRA1GABRA5GABRA3GABRA2GABRG2 | |
| SCHEMBL5350970 | 0.79 | GABRA1 (0.68) | GABRA1GABRA5GABRA3GABRA2GABRG2 | |
| SCHEMBL11015792 | 0.78 | GABRA1 (0.68) | GABRA1GABRA5GABRA3GABRA2GABRG2 | |
| SCHEMBL7720989 | 0.78 | GABRA1 (0.77) | GABRA1GABRA5GABRA3GABRA2GABRG2 | |
| SCHEMBL11512290 | 0.77 | LMNA (0.44) | GABRA1GABRA5GABRA3GABRA2GABRG2 | |
| Ro-052921 SCHEMBL29979594 | 0.77 | GABRA1 (1.00) | GABRA1GABRA5GABRA3GABRA2GABRG2 | |
| Ro-052921 SCHEMBL1365706 | 0.77 | GABRA1 (1.00) | GABRA1GABRA5GABRA3GABRA2GABRG2 | |
| SCHEMBL13501730 | 0.77 | GABRA1 (0.54) | GABRA1GABRA5GABRA3GABRA2GABRG2 | |
| SCHEMBL2615411 | 0.75 | GABRA1 (0.78) | GABRA1GABRA5GABRA3GABRA2GABRG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090062256-A1 | LACTAMS SUBSTITUTED BY CYCLIC SUCCINATES AS INHIBITORS OF Abeta PROTEIN PRODUCTION | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2009-03-05 | — | — | US | disclosed |
| US-20090062256-A1 | LACTAMS SUBSTITUTED BY CYCLIC SUCCINATES AS INHIBITORS OF Abeta PROTEIN PRODUCTION | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2009-03-05 | — | — | US | disclosed |
| US-20080103128-A1 | LACTAMS SUBSTITUTED BY CYCLIC SUCCINATES AS INHIBITORS OF ABETTA PROTEIN PRODUCTION | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2008-05-01 | — | — | US | disclosed |
| US-20080103128-A1 | LACTAMS SUBSTITUTED BY CYCLIC SUCCINATES AS INHIBITORS OF ABETTA PROTEIN PRODUCTION | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2008-05-01 | — | — | US | disclosed |
| US-7354914-B2 | Lactams substituted by cyclic succinates as inhibitors of Aβ protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2008-04-08 | — | — | US | disclosed |
| US-7354914-B2 | Lactams substituted by cyclic succinates as inhibitors of Aβ protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2008-04-08 | — | — | US | disclosed |
| EP-0135770-A2 | Imidazobenzodiazepine derivatives, process for their preparation and medicaments containing them | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1985-04-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062256-A1 | LACTAMS SUBSTITUTED BY CYCLIC SUCCINATES AS INHIBITORS OF Abeta PROTEIN PRODUCTION | BACE1, APP, APH1A | GABRA1 694/4885GABRA5 389/4885GABRA3 1002/4885 |
| US-20080103128-A1 | LACTAMS SUBSTITUTED BY CYCLIC SUCCINATES AS INHIBITORS OF ABETTA PROTEIN PRODUCTION | APH1A, APH1B, APP | GABRA1 324/4885GABRA5 220/4885GABRA3 486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.